作者
Donald P Tashkin, Robert Elashoff, Philip J Clements, Michael D Roth, Daniel E Furst, Richard M Silver, Jonathan Goldin, Edgar Arriola, Charlie Strange, Marcy B Bolster, James R Seibold, David J Riley, Vivien M Hsu, John Varga, Dean Schraufnagel, Arthur Theodore, Robert Simms, Robert Wise, Fred Wigley, Barbara White, Virginia Steen, Charles Read, Maureen Mayes, Ed Parsley, Kamal Mubarak, M Kari Connolly, Jeffrey Golden, Mitchell Olman, Barri Fessler, Naomi Rothfield, Mark Metersky, Dinesh Khanna, Ning Li, Gang Li, Scleroderma Lung Study Research Group*
发表日期
2007/11/15
期刊
American journal of respiratory and critical care medicine
卷号
176
期号
10
页码范围
1026-1034
出版商
American Thoracic Society
简介
Rationale: The Scleroderma Lung Study enrolled 158 patients with scleroderma-related interstitial lung disease in a placebo-controlled trial of oral cyclophosphamide (CYC). Although treatment-related benefits in pulmonary function, skin scores, and patient-centered outcomes were demonstrated after 1 year of therapy, the duration of benefit beyond 1 year was unclear.
Objectives: A second year of follow-up was performed to determine if these effects persisted after stopping treatment.
Methods: A detailed analysis of data obtained over the two years of the study was performed.
Measurements and Main Results: Using a longitudinal joint model, we analyzed FVC, total lung capacity, transitional dyspnea index, Rodnan skin scores, and the Health Assessment Questionnaire–Disability Index during the second year, after adjusting for baseline values, baseline fibrosis score, and nonignorable missing data. Evaluable …
引用总数
学术搜索中的文章
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease
DP Tashkin, R Elashoff, PJ Clements, MD Roth… - American journal of respiratory and critical care …, 2007